Xoma Corp. said Wednesday it was issued a fundamental U.S.patent covering DNA sequences and the production of humanbactericidal/permeability increasing protein (BPI) usingrecombinant technology.
Xoma (NASDAQ:XOMA) of Berkeley, Calif., said it is theexclusive licensee of the patent, No. 5,198,541, for humantherapeutic and diagnostic applications. The company isinvestigating BPI for use in the treatment of Gram-negativesepsis, acute and chronic focal infections and other possibleclinical applications.
Xoma began a Phase I study earlier this month on rBPI-23, agenetically engineered fragment of the human BPI protein,designed to assess the safety and pharmacokinetics of thecompound under an investigational new drug application filedwith the FDA.
(c) 1997 American Health Consultants. All rights reserved.